India continues to bear a significant portion of the global tuberculosis (TB) burden, accounting for approximately 25% of new cases worldwide according to the latest World Health Organization (WHO) Global TB Report. Despite remarkable progress, with TB incidence declining by 21% from 237 to 187 cases per lakh population between 2015 and 2024, challenges persist in achieving treatment success for all patients. A groundbreaking study from the Indian Council of Medical Research's National Institute for Research in Tuberculosis (ICMR-NIRT) in Chennai sheds new light on why some individuals fail to respond adequately to standard anti-TB therapy. Researchers have identified that an overzealous immune response, characterized by excessive activation of the complement system early in the disease, may predict a higher risk of treatment failure.

This discovery, detailed in a peer-reviewed publication in Frontiers in Immunology, highlights the role of immune dysregulation in pulmonary TB outcomes. While over 90% of TB patients recover with standard six-month regimens under India's National TB Elimination Programme (NTEP), the remaining subset experiences unfavorable results such as treatment failure, death, or recurrence. Understanding these immune signatures could revolutionize risk stratification and personalized care.

Understanding the Complement System in TB Immunity

The complement system, a critical component of the innate immune response, comprises over 30 proteins that work together to tag and destroy pathogens like Mycobacterium tuberculosis (Mtb), the bacterium causing TB. Activation occurs via classical, alternative, or lectin pathways, leading to opsonization, inflammation, and cell lysis. In TB, Mtb deploys evasion strategies, such as capsular polysaccharides, to resist complement-mediated killing. However, when the system becomes hyperactive—described as 'overzealous'—it triggers excessive inflammation, damaging lung tissue and impairing bacterial clearance.

ICMR-NIRT researchers focused on plasma levels of complement activation products and regulators. Prior studies from the institute have linked baseline inflammatory markers like acute phase proteins (APPs) and cytokines such as IL-6 to poor outcomes, but this is the first comprehensive complement profiling in an Indian cohort. The work builds on global evidence that immune imbalance contributes to 5-10% treatment failures in drug-sensitive TB.

Methodology of the ICMR-NIRT Study

Published on February 11, 2026, the study (DOI: 10.3389/fimmu.2026.1679947) employed a nested case-control design within the EDOTS cohort from 2014-2019 in Chennai. Researchers analyzed plasma from 176 adults (18-75 years) with newly diagnosed, smear- and culture-positive pulmonary TB. Cases (n=68) had unfavorable outcomes: treatment failure (n=18), death (n=16), or recurrence (n=34). Controls (n=108) achieved cure without recurrence. Matching was done 1:1.6 by age, gender, body mass index (BMI), and diabetes status to control confounders common in India, where 20-30% of TB patients have diabetes.

Blood samples were collected at baseline (pre-treatment) and after two months of standard anti-TB therapy. Complement proteins—including C1q, C3, C3b/iC3b, C4, C4b, C5, C5a, MBL, Factor B, D, H, and I—were quantified using a Luminex Magpix multiplex assay. Statistical rigor included Mann-Whitney U tests for group differences, Wilcoxon signed-rank for pre/post changes, and generalized linear models adjusted for smoking, alcohol, and comorbidities. Receiver Operating Characteristic (ROC) curves assessed predictive accuracy.

Exclusion criteria ensured focus on drug-sensitive TB: no prior treatment, drug resistance, HIV, or immunosuppression. Ethical approval came from ICMR-NIRT's institutional committee, with funding from India's Department of Biotechnology (DBT) and US NIH.

Key Findings: Biomarkers of Dysregulated Complement Activation

At baseline, patients with poor outcomes exhibited significantly elevated levels of classical pathway activators: C1q (p<0.0001), C4b (p=0.0007), C3/C3b (p<0.0001), C5/C5a (p<0.0001). Regulatory proteins Factor B and H were lower (p<0.0001 at month two). These patterns persisted after two months, indicating sustained dysregulation rather than transient response.

• C5 showed the highest ROC AUC (0.875) for predicting recurrence vs. cure.
• C1q (AUC 0.864) and C3b (0.715) also discriminated well.
• Multivariate regression confirmed associations: adjusted odds ratios (aOR) for C5 (3.31), C4b (4.02), C1q (2.43).

Lead researcher Nathella Pavan Kumar noted, "Early and sustained complement activation, particularly through the classical pathway, is associated with adverse outcomes in TB." This overactivation likely amplifies inflammation, promoting fibrosis and cavitation, hallmarks of treatment-resistant disease.

Photo by Markus Winkler on Unsplash

Mechanisms Behind Overzealous Immune Response in TB

Mtb survives within macrophages by inhibiting phagosome-lysosome fusion and resisting complement deposition. In susceptible hosts, unchecked classical pathway activation (triggered by Mtb antibodies binding C1q) generates anaphylatoxins like C5a, recruiting neutrophils that cause collateral lung damage. Low Factor H fails to inhibit C3 convertase, perpetuating the cycle.

In India, where malnutrition affects 20-30% of TB patients and diabetes doubles failure risk, these dynamics are exacerbated. NIRT's prior work on APPs like CRP and cytokines (e.g., baseline IL-6 predicting failure) complements this, suggesting a hyperinflammatory profile. Hyperinflammation mirrors 'TB immunopathology,' akin to COVID-19 cytokine storms, where immune excess harms more than the pathogen.

Implications for TB Management in India

With NTEP notifying over 2.5 million cases annually via Ni-kshay portal, integrating complement biomarkers could triage high-risk patients for intensified monitoring, nutritional support, or adjunctive anti-inflammatories. Cost-effective multiplex assays like Luminex make this feasible in district labs.

Dr. Vijay Viswanathan, senior diabetologist, explained: "Complement proteins act like a back-up force... but if too active, they cause harmful inflammation." For India's 187/lakh incidence, predicting the 10% failure rate could save lives and reduce DR-TB emergence (now 2-3% in new cases).

Opportunities include linking to clinical research jobs at institutes like NIRT, where experts develop these tools.

NIRT's Broader Contributions to TB Biomarker Research

ICMR-NIRT, Chennai, leads TB immunology, with studies on IL-6 (baseline biomarker for failure), chitinase/IDO (prognostic in DR-TB), and cytokine profiles distinguishing cured vs. recurrent cases. Recent 2025-2026 work includes plasma biomarkers for progression in household contacts and CMV co-infection impacts.

This complement study extends EDOTS cohort insights, aligning with global efforts like RePORT India for harmonized data.

Challenges and Future Directions

TB treatment failure rates hover at 5-10% in drug-sensitive cases, higher in high-burden areas like Northeast India (ICMR-NIRT reports). Malnutrition, diabetes (15-20% co-prevalence), and delayed diagnosis fuel risks. Validating biomarkers in diverse populations, developing point-of-care tests, and trials of complement inhibitors (e.g., eculizumab analogs) are next steps.

India's push for shorter regimens (e.g., six-month BPaL for DR-TB, cost-saving per ICMR) complements this. For researchers eyeing research jobs in higher ed, NIRT offers opportunities in immunology.

Photo by Guido Hofmann on Unsplash

Towards TB Elimination: Actionable Insights

By front-loading biomarkers, NTEP can optimize resource allocation, reducing the Rs. 10,000-20,000 per failure cost. Community engagement via Ni-kshay and private sector integration (90% success) will amplify impact.

Stakeholders—from policymakers to clinicians—should prioritize validation studies. Aspiring professionals can explore career advice for TB research roles.

Conclusion: A Step Forward in Precision TB Care

The ICMR-NIRT TB immune response study underscores how overzealous complement activation forecasts trouble, paving the way for proactive interventions. As India nears 2025 elimination goals, such research fortifies the arsenal. Stay informed and contribute via Rate My Professor, Higher Ed Jobs, or Career Advice at AcademicJobs.com. For openings in clinical research, visit Clinical Research Jobs and University Jobs.